Prescribing guide
Firazyr (icatibant)On-demand dosing, repeat-dose limits, laryngeal attack counseling, generic icatibant and prior authorization criteria for hereditary angioedemaFor prescribers and their offices treating hereditary angioedema (HAE): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS; prescription and Takeda Patient Support Start Form (online or fax), prior authorization, specialty pharmacy dispensing, and self-injection training before the first attack treated at home.
Example PA threshold
Cigna example: HAE type I or II with functional C1-INH under 50% and low C4, both documented; allergist, immunologist or HAE specialist; generic icatibant before brand Firazyr; up to 30mg per injection, no more than three times daily.
Monitoring
No scheduled lab monitoring in the label; counsel on laryngeal attacks and immediate medical attention; injection site reactions in 97%; repeat dosing at 6 hours or more, maximum 3 doses in 24 hours.
Support line
Takeda Patient Support, 1-866-888-0660, Monday to Friday 8:30 AM to 8:00 PM ET; enroll at TakedaPatientSupport.com/HCP or by faxed Start Form; co-pay help up to 100% of out-of-pocket co-pay costs to an annual maximum for commercial plans.
Give your patient their plan
A one-page handout for starting Firazyr, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/firazyrBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| No REMS | The label sets no REMS, no boxed warning and no contraindications, and Firazyr does not appear on the FDA REMS list. | FDA REMS list |
| Enrollment | Enroll the patient in Takeda Patient Support online at TakedaPatientSupport.com/HCP or by faxing the completed Firazyr Start Form. | Takeda prescriber page |
| Program services | Benefits investigation, specialty pharmacy or site of care triage and coordination, co-pay program enrollment for eligible patients, and product administration training, at home if the office requests it. | Takeda prescriber page |
| Brand or generic | Drugs@FDA lists 8 generic icatibant acetate injections (30mg/3mL) with TE code AP against Firazyr. Check the plan's preferred product before writing for the brand. | Drugs@FDA |
| Pack size | Cartons hold 1 single-dose prefilled syringe and 1 25G Luer lock needle (NDC 54092-702-02); a pack of 3 cartons is also supplied (NDC 54092-702-03). Each attack dose uses 1 syringe, and up to 3 doses are allowed in 24 hours. | FDA label |
| Self-injection training | Patients may self-administer upon recognition of symptoms of an HAE attack after training under the guidance of a healthcare professional. | FDA label |
| Laryngeal attack counseling | Advise patients with laryngeal symptoms to seek medical attention immediately in an appropriate healthcare facility after administration. | FDA label |
| Driving | Tiredness, drowsiness and dizziness have been reported; advise patients not to drive or use machinery if they feel tired or dizzy. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: Cigna, January 1, 2026. Approval approved a year at a time. Renewal asks for the documented diagnosis and a favorable response to icatibant, according to the prescriber. This version took effect January 1, 2026. It cites the October 2021 Firazyr prescribing information, which predates the June 2025 label. The policy covers brand Firazyr, generic icatibant and Sajazir. Its 2026 update removed a rule against using icatibant with other attack medicines. Other plans set their own criteria. It is here as an example, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | HAE type I or II, with functional C1-INH protein below 50% of normal at baseline | C1-INH functional lab report with reference range [documentation required] | Cigna policy |
| C4 | Serum C4 below normal at baseline | C4 lab report with reference range [documentation required] | Cigna policy |
| HAE with normal C1-INH | Separate criteria: normal C1-INH and C4 [documentation required], attacks not responsive to high-dose oral H1 antihistamines per the prescriber, and a confirmed pathogenic variant (F12, PLG, ANGPT1, KNG1, MYOF or HS3OST6) or, with no variant identified, a family history | Lab reports, genetic test report, family history in the chart | Cigna policy |
| Prescriber | Prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders | Specialty on the request, or the consult note | Cigna policy |
| Brand Firazyr | Non-preferred. Patient has tried generic icatibant (or Sajazir, on Individual and Family Plans) and cannot continue because of a formulation difference in the inactive ingredients which, per the prescriber, would result in a significant allergy or serious adverse reaction | Chart note on the generic trial and the reaction [documentation required] | Cigna policy |
| Dosing | Up to 30mg per injection, subcutaneously, no more frequently than three times daily; other doses reviewed case by case | Dose and directions on the request | Cigna policy |
| Not covered | HAE prophylaxis; icatibant is not indicated for prophylaxis of HAE attacks | Indication on the request: treatment of acute attacks | Cigna policy |
| Continuation | Diagnosis [documentation required] and, per the prescriber, a favorable clinical response such as shorter attacks, quick onset of symptom relief, complete resolution of symptoms, or fewer or less severe attacks; approval for 1 year | Attack and treatment record in the chart | Cigna policy |
Firazyr dosing and titration
| When | Label | Source |
|---|---|---|
| Each attack | 30mg subcutaneously in the abdominal area, over at least 30 seconds. | FDA label |
| Repeat dosing | Additional 30mg doses at intervals of at least 6 hours if response is inadequate or symptoms recur. | FDA label |
| Maximum | No more than 3 doses in any 24-hour period. | FDA label |
| Laryngeal attack | Treat, and advise the patient to seek medical attention in an appropriate healthcare facility immediately. | FDA label |
| Preparation | Inspect for particulates and discoloration; solution should be clear and colorless. Attach the provided 25 gauge needle; do not use a different needle. | FDA label |
| Presentation | Single-dose prefilled syringe delivering 30mg in 3mL (10mg per mL); plunger stopper not made with natural rubber latex. | FDA label |
| Pharmacokinetics | Cmax at about 0.75 hours; mean elimination half-life 1.4 hours; no accumulation after three 30mg doses 6 hours apart. | FDA label |
| Special populations | No dose adjustment for hepatic or renal impairment, age or gender. Not established under 18 years. | FDA label |
| Storage | 2°C to 25°C (36°F to 77°F); do not freeze; store in the carton until administration. | FDA label |
Monitoring the Firazyr label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each laryngeal attack | Airway | Potential for airway obstruction; immediate medical attention in an appropriate healthcare facility in addition to treatment | FDA label |
| After each dose | Response | Median time to 50% symptom reduction 2.0 hours against 19.8 hours on placebo in Trial 1; redose at 6 hours or more if inadequate or symptoms recur | FDA label |
| After each dose | Injection site reactions | 97% against 33% on placebo in the placebo-controlled trials | FDA label |
| Placebo-controlled trials | Pyrexia, transaminase increase, dizziness | Pyrexia 4% against 0%, transaminase increased 4% against 0%, dizziness 3% against 1%; no routine monitoring specified | FDA label |
| Postmarketing | Urticaria | Reported during post-approval use; no hypersensitivity or anaphylactic reactions were reported in the trials | FDA label |
| Immunogenicity | Anti-icatibant antibodies | 4 patients tested positive across repeated treatment, 3 later negative; no association with efficacy | FDA label |
| Renewal | Clinical response to icatibant | Cigna approves 1 year at a time; continuation needs a favorable response according to the prescriber | Cigna policy |
Firazyr drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| ACE inhibitors | Potential pharmacodynamic interaction; Firazyr may attenuate the antihypertensive effect of ACE inhibitors. Clinical trials excluded subjects taking ACE inhibitors. | FDA label |
| CYP450 substrates, inhibitors and inducers | No formal interaction studies. Icatibant is not metabolized by CYP450 enzymes and did not significantly inhibit or induce them in vitro; metabolic interactions are not expected. | FDA label |
| Elderly patients | About 2-fold higher AUC than in younger adults after a single 30mg dose; no differences in efficacy or safety identified and no dose adjustment recommended. | FDA label |
| Pregnancy | Published literature and pharmacovigilance data have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Premature birth and abortion occurred in rabbits at about 0.025 times the MRHD. | FDA label |
| Lactation | No data on icatibant in human milk; present in rat milk. Systemic absorption in infants is not expected after oral exposure through breast milk. | FDA label |
| QT interval | A thorough QT study of 30mg and 90mg single doses found no effect above the 10 ms threshold of regulatory concern. | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedCigna asks for a functional C1 inhibitor level under 50% of normal and a low C4 level, each with lab documentation. It also wants an allergist, immunologist or HAE specialist. The office sends both lab reports.
- The plan wants generic icatibant, not brand FirazyrCigna lists Firazyr as non-preferred. Its policy asks that the patient tried generic icatibant and cannot continue because of an inactive ingredient difference. The prescriber must document that it would cause a significant allergy or serious adverse reaction.
- HAE with normal C1 inhibitorCigna covers icatibant for this type under separate criteria. They include normal C1 inhibitor and C4 results, attacks that did not respond to high-dose antihistamines, and a confirmed gene variant or a family history.
- A request to use it for preventionCigna does not cover icatibant to prevent attacks, and says it is not indicated for that use. The Firazyr label approves it only to treat acute attacks.
- A dose the plan will not coverCigna approves up to 30mg per injection, no more often than three times daily. Other doses go to case-by-case review by a Cigna clinician.
- A renewal after the first yearCigna approves icatibant for 1 year at a time. For renewal, the prescriber confirms a favorable response, such as shorter attacks, quick symptom relief or complete resolution of symptoms.
- A copay you cannot payWith commercial insurance, the Takeda co-pay program can cover up to 100% of out-of-pocket co-pay costs, up to a yearly maximum. Medicare, Medicaid, TRICARE, VA and other government plans are excluded. Takeda says it may connect people who cannot afford treatment to other programs.
- The plan uses a co-pay maximizerTakeda says it may lower or end co-pay help for people in a plan with a co-pay maximizer program. Its terms ask you to notify the program right away if you learn your plan uses one.
Takeda Patient Support
- Support specialists who answer questions and help with the health insurance process
- The Takeda Patient Support Co-Pay Assistance Program for commercial insurance, including Marketplace plans, covering up to 100% of out-of-pocket co-pay costs up to a yearly maximum
- No co-pay help for Medicare, Medicare Advantage, Medicaid, TRICARE, VA or other federal or state plans
- Work with your specialty pharmacy or site of care to get your prescribed treatment to you
- In-home injection training from a specially trained nurse
- Directions to community support resources and education
- Possible help in another language if English is not your preferred language
- For the office, a benefits investigation and enrollment online or by faxed Start Form Takeda prescriber page
Questions prescribers' offices ask about Firazyr
What is the Firazyr dose for an acute HAE attack?
30mg subcutaneously in the abdominal area, per the June 2025 label (section 2.1). Additional 30mg doses may be given at intervals of at least 6 hours if response is inadequate or symptoms recur, with no more than 3 doses in any 24-hour period.
Does Firazyr have a REMS or required lab monitoring?
No. The June 2025 label has no REMS, no boxed warning, no contraindications and no scheduled lab monitoring, and Firazyr is not on the FDA REMS list. The one warning is laryngeal attacks: advise patients to seek medical attention in an appropriate healthcare facility immediately in addition to treatment (section 5.1).
What should patients be told about laryngeal attacks?
Section 5.1 of the June 2025 label says patients should be advised to seek medical attention in an appropriate healthcare facility immediately, in addition to treatment with Firazyr, given the potential for airway obstruction. The Patient Information tells them to inject and then go to the nearest hospital emergency room right away. In the controlled trials, 60 patients with laryngeal attacks were treated, with efficacy similar to other sites.
Is generic icatibant interchangeable with Firazyr?
Drugs@FDA lists 8 generic icatibant acetate injections, 30mg/3mL, with TE code AP against Firazyr (NDA 022150) as of November 11, 2026. The June 2025 Firazyr label does not address generics. The Cigna policy shown here makes brand Firazyr non-preferred behind generic icatibant.
What do insurers ask for to approve icatibant?
The Cigna policy shown here, effective January 1, 2026, asks for HAE type I or II with functional C1-INH under 50% of normal and a low C4, both documented, and an allergist, immunologist or HAE specialist. Approval is for 1 year. Brand Firazyr also needs a documented trial of generic icatibant that could not continue because of an inactive-ingredient difference. HAE with normal C1-INH has its own criteria. The policy cites the October 2021 prescribing information.
Free email alert
Get an email when the Firazyr label changes
One email the day the FDA revises the Firazyr prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Firazyr only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - FIRAZYR- icatibant acetate injection, solution (prescribing information revised 6/2025, Patient Information and Instructions for Use revised June 2025), Takeda Pharmaceuticals America, Inc., via DailyMed, 2025-07-07.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, 2026-11-11.
- FIRAZYR® (icatibant injection) | Information for Patients, Takeda, 2026-11-11.
- FIRAZYR® (icatibant injection) | Clinical Information for Healthcare Professionals, Takeda, 2026-11-11.
- Hereditary Angioedema - Icatibant, Drug Coverage Policy IP0335, Cigna, 2026-01-01.
- Drugs@FDA: FDA-Approved Drugs, New Drug Application (NDA) 022150, FIRAZYR, FDA, 2026-11-11.
- NDA 22150/S-016 supplement approval letter, patient labeling and instructions for use, replacement needle, FDA, 2024-01-19.
- NDA 22150/S-012 and S-013 supplement approval letter, Pregnancy and Lactation Labeling Rule update and postmarketing urticaria, FDA, 2020-04-16.
- NDA 22150/S-007 supplement approval letter, mouse carcinogenicity study results in Section 13.1, FDA, 2015-11-24.
- NDA 22150/S-004 supplement approval letter, rat carcinogenicity study results in Section 13.1, FDA, 2013-08-30.
- NDA 022150 approval letter, Firazyr (icatibant acetate) Injection, FDA, 2011-08-25.
A reference drawn from the July 7, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 11, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.